FDA says Geodon journal ad omits risk info

Share this content:
The FDA says a professional journal ad for Pfizer's antipsychotic medication Geodon (ziprasidone mesylate) for injection omits important risk info and contains unsubstantiated superiority claims. It wants the company to submit a list of all materials to be pulled along with a plan for discontinuing its use, and Pfizer has agreed.

Share this content:
Scroll down to see the next article